- Home
- ARQT vs COLL Comparison
ARQT vs COLL Comparison
Compare ARQT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | COLL |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.5B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARQT | COLL |
|---|---|---|
| Price | $28.60 | $48.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $24.83 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 2.4M | 515.8K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $317,929,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $85.51 | $26.35 |
| Revenue Next Year | $30.74 | $3.67 |
| P/E Ratio | ★ N/A | $29.92 |
| Revenue Growth | ★ 129.21 | 26.34 |
| 52 Week Low | $11.13 | $23.23 |
| 52 Week High | $31.77 | $49.16 |
Technical Indicators
Market Signals| Indicator | ARQT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 67.43 |
| Support Level | $28.30 | $47.86 |
| Resistance Level | $31.77 | $49.16 |
| Average True Range (ATR) | 1.12 | 1.35 |
| MACD | -0.48 | -0.20 |
| Stochastic Oscillator | 11.53 | 76.68 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.